专访诺贝尔奖得主马里奥·卡佩奇：中国政府对科研支持力度更大

Core Insights - Cell and gene technology is becoming a crucial area of innovation in biomedicine, offering new possibilities for human health, but its development is constrained by policy direction, financing environment, and ethical norms [1][4] - Mario Capecchi, a Nobel laureate, emphasizes the foundational role of genes in biological research while acknowledging the significant influence of environmental factors [1][4] - Capecchi praises China's leading achievements in gene therapy and highlights the government's strong support for scientific research, contrasting it with the declining scientific enthusiasm in the U.S. due to policy changes [4][5] Group 1: Scientific Exploration and Challenges - Capecchi encourages researchers to contribute to future advancements, stressing the importance of overcoming challenges in scientific exploration, particularly in gene modification [2][6] - He notes that scientific research is a continuous process that often involves failure, and researchers must learn to coexist with change and setbacks [6][7] - Capecchi believes that the significance of data in research is sometimes overstated, advocating for practical assessments of experimental outcomes rather than relying solely on complex data analysis [6][7] Group 2: Market and Economic Aspects - The global cell and gene therapy market was valued at $5.8 billion in 2022 and is projected to grow to $23.33 billion by 2028, with a compound annual growth rate (CAGR) of 26.4% [7] - In China, the CGT market reached approximately 3.38 billion yuan in 2023, a 113.64% increase from the previous year, with expectations to grow to 8.84 billion yuan in 2024 and 18.63 billion yuan in 2025 [7] - Capecchi highlights the importance of reducing drug prices to ensure accessibility for patients, noting that market competition will drive down costs as demand increases [6][7]